Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss
Continuing to Deliver on the America First Global Health Strategy with the Signing of the United States-Rwanda Bilateral Health Cooperation Memorandum of Understanding - United States Department of State